Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States

Human Vaccines and Immunotherapeutics - Tập 17 Số 2 - Trang 332-343 - 2021
Sandra E. Talbird1, Elizabeth M. La1, Justin Carrico1, Sara Poston2, Jean‐Etienne Poirrier2, Jessica K. DeMartino2, Cosmina Hogea3
1Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
2US Health Outcomes & Epidemiology, Vaccines, GSK, Philadelphia, PA, USA
3Global Value Evidence and Outcomes, Oncology,GSK, Philadelphia, PA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1007/s10935-015-0394-3

10.1377/hlthaff.2016.0462

Centers for Disease Control and Prevention. Immunization Schedule for Adults (19 Years of Age and Older). [accessed 2019 Jan 15]. https://www.cdc.gov/vaccines/schedules/hcp/adult.html

Centers for Disease Control and Prevention. Vaccination Coverage Among Adults in the United States National Health Interview Survey 2016. [accessed 2019 Jan 15]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2016.html

10.1186/s12877-017-0420-9

10.1093/infdis/jis240

10.1016/j.vaccine.2015.11.004

10.1093/gerona/gly150

10.1111/j.1532-5415.2010.03021.x

10.1093/cid/ciu156

United States Census Bureau. Projected Population by Age Sex Race and Hispanic Origin: 2014 to 2060 [accessed 2019 Jan 15]. https://www.census.gov/data/datasets/2014/demo/popproj/2014-popproj.html

Acosta A. Cost-effectiveness of pertussis vaccine substitution for tetanus booster in prevention of pertussis in adults 65 years and older. Presentation to the Advisory Committee on Immunization Practices (ACIP). Atlanta (GA): US Department of Health and Human Services, CDC; 2012.

10.1080/21645515.2016.1186313

10.1016/j.vaccine.2019.09.104

10.1186/s12879-015-1269-1

10.1586/erp.11.94

Centers for disease control and prevention. Influenza vaccination coverage estimates for persons 6 months and older by state HHS region and the United States National Immunization Survey-Flu (NIS-Flu) and Behavioral Risk Factor Surveillance System (BRFSS) 2010-11 through 2016-17 influenza seasons. 2017. [accessed 2018 Feb 20]. https://www.cdc.gov/flu/fluvaxview/reportshtml/trends/index.html

Centers for Disease Control and Prevention. AdultVaxView Vaccination Coverage Among Adults in the United States National Health Interview Survey 2016. 2018. [accessed 2018 Feb 20]. https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/NHIS-2016.html

10.15585/mmwr.mm6453a1

Bresee J, Reed C, Kim IK, Finelli L, Fry A, Chaves SS, Burns E, Gargiullo P, Jernigan D, Cox N, et al. Estimated influenza illnesses and hospitalizations averted by influenza vaccination — United States, 2012–13 influenza season. MMWR Morb Mortal Wkly Rep. 2013;62:997–1000.

Centers for Disease Control and Prevention. Active Bacterial Core Surveillance report Emerging Infections Program Network Streptococcus pneumoniae. 2013. Atlanta (GA): Centers for Disease Control and Prevention; 2013.

Centers for Disease Control and Prevention. Estimated Influenza Illnesses and Hospitalizations Averted by Vaccination — United States 2014–15 Influenza Season. 2015. [accessed 2016 Apr 20]. http://www.cdc.gov/flu/about/disease/2014-15.htm

Centers for Disease Control and Prevention. Estimated Influenza Illnesses Medical Visits Hospitalizations and Deaths Averted by Vaccination in the United States. 2017. [accessed 2019 Mar 28]. https://www.cdc.gov/flu/about/disease/2015-16.htm

10.1186/s12879-015-1262-8

10.1371/journal.pone.0066312

Reed C, Kim IK, Singleton JA, Chaves SS, Flannery B, Finelli L, Fry A, Burns E, Gargiullo P, Jernigan D, et al. Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season. MMWR Morb Mortal Wkly Rep. 2014;63(49):1151–54.

10.1007/s11606-016-3651-0

10.1016/j.vaccine.2008.07.016

10.1016/S2213-2600(14)70032-3

10.1056/NEJMoa1408544

Centers for disease control and prevention. Past Seasons Vaccine Effectiveness Estimates 2018. [accessed 2019 Dec 12]. https://www.cdc.gov/flu/vaccines-work/past-seasons-estimates.html

10.1056/NEJMoa1603800

10.1056/NEJMoa1501184

10.1016/j.vaccine.2018.07.005

10.1016/j.vaccine.2016.02.027

10.1007/s12325-014-0115-y

10.1093/cid/ciu918

10.1001/jama.2012.169

Centers for Disease Control and Prevention. 2017 Behavioral risk factor surveillance system survey data and documentation. [accessed 2019 Jan 15]. https://www.cdc.gov/brfss/annual_data/annual_2017.html

Zostavax prescribing information. [accessed 2019 Jan 15]. https://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf

Centers for Disease Control and Prevention. Vaccine recommendations and guidelines of the ACIP: vaccine-specific recommendations (by date published). 2019. [accessed 2020 Jan 14]. https://www.cdc.gov/vaccines/hcp/acip-recs/recs-by-date.html

10.7326/M17-3439

Shingrix prescribing information. [accessed 2019 Jan 15]. https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF

Patterson BJ, Cheng WY, Trofa AF, Duchesneau A, Macheca M, Masseria C, Duh MS A claims-based analysis of hepatitis A, B and A/B vaccination series completion and compliance among US adults. ISPOR 22nd Annual International Meeting. Boston, MA, USA, 2017.

Arias E, Heron M, Xu J. United States life tables, 2014. Natl Vital Stat Rep. 2017;66.

10.1080/13696998.2018.1542520

10.1086/258535

U.S. Department of Health & Human Services. National Adult Immunization Plan. 2016. [accessed 2019 April 10]. https://www.hhs.gov/sites/default/files/nvpo/national-adult-immunization-plan/naip.pdf

Centers for Disease Control and Prevention. Strategies for Increasing Adult Vaccination Rates. 2016. [accessed 2019 Mar 7]. https://www.cdc.gov/vaccines/hcp/adults/for-practice/increasing-vacc-rates.html

10.15585/mmwr.mm6740a4

10.1016/j.vaccine.2019.01.010

Akinbosoye OETM, Grana J, Macpherson C. Factors associated with zostavax abandonment. Am J Pharm Benefits. 2016;8:84–89.

10.3390/vaccines6040078

10.1080/03007995.2017.1416347

National quality forum. Priority setting for healthcare performance measurement: addressing performance measure gaps for adult immunizations. 2014. [accessed 2019 Apr 10]. https://www.qualityforum.org/Publications/2014/08/Priority_Setting_for_Healthcare_Performance_Measurement__Addressing_Performance_Measure_Gaps_for_Adult_Immunizations.aspx

10.1016/j.vaccine.2019.01.044

HEDIS 2020 Volume 2. Appendix 1: summary table of measures product lines and changes. 2020. [accessed 2020 May 6]. https://www.ncqa.org/wp-content/uploads/2019/07/20190701_HEDIS_2020_Measures_Summary_of_Changes.pdf

10.3389/fimmu.2013.00171

10.1016/j.vaccine.2014.07.013

10.1093/infdis/jiy103

Navarro-Torné A, Hanrahan F, Kerstiëns B, Aguar P,LM. Public health–driven research and innovation for next-generation influenza vaccines, European Union. Emerg Infect Dis. 2019;25(2). https://doi.org/10.3201/eid2502.180359

Matanock A Considerations for PCV13 use among adults ≥65 years old and a summary of the evidence to recommendations framework. Advisory committee on immunization practices june 2019 meeting. 2019. [accessed 2019 Nov 13]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/Pneumococcal-2-Matanock-508.pdf

Havers F. Tdap and Td: summary of Work Group considerations and proposed policy options. 2019. [accessed 2019 Dec 11]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2019-10/Pertussis-03-Havers-508.pdf